1月30日晚间,复旦张江(688505.SH 01349.HK)发布2025年年度业绩预告。公告显示,公司当期业绩虽面临短期压力,但在创新药研发领域持续加码,ADC(抗体偶联剂)与光动力药物管线进展显著,为长期发展筑牢技术壁垒。根据业绩预告,经公司财务部门初步测算,2025年1-12月,复旦张江预计实现归属于母公司所有者的净利润为-1.8亿元至-1.2亿元,较上年同期由盈转亏;归属于母公司所有者的...
Source Link1月30日晚间,复旦张江(688505.SH 01349.HK)发布2025年年度业绩预告。公告显示,公司当期业绩虽面临短期压力,但在创新药研发领域持续加码,ADC(抗体偶联剂)与光动力药物管线进展显著,为长期发展筑牢技术壁垒。根据业绩预告,经公司财务部门初步测算,2025年1-12月,复旦张江预计实现归属于母公司所有者的净利润为-1.8亿元至-1.2亿元,较上年同期由盈转亏;归属于母公司所有者的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.